Migraine is the 6th most disabling disease, while headaches collectively are the 3rd most disabling.

- **1 IN 6 Americans**: Over 50 million men, women and children suffer from migraine in the United States.
- **2X**: Migraine affects women more than twice as often as men.
- **25-55 years old**: Migraine most often affects patients in middle life, when they are most productive in their careers and family life.
- **3RD**: Migraine is the 3rd most common disease around the world.

**DISEASE BURDEN**

- **$78B**: Estimated annual direct and indirect U.S. health care costs from migraine.
- **$41B**: Sufferers spent over $41B total on treating their entire range of conditions.

**LOST PRODUCTIVITY: MIGRAINE COST EMPLOYERS NEARLY $13B ANNUALLY RESULTING FROM 113 MILLION LOST WORK DAYS DUE TO THE CONDITION**

- **$21.5M**: Estimated annual corporate losses due to migraine-related absences from the workplace.
- **$24.4M**: Estimated annual corporate losses from reduced on-the-job productivity.

**UNMET NEED**

Until very recently, there were no preventative options developed specifically for migraine. For many patients, existing options were either hard to tolerate or moderately effective.

- **68%**: 68% of employed migraine sufferers reported being less productive at work.
- **72%**: 72% of migraine sufferers said their disease affects their ability to care for their loved ones.

If all migraine sufferers not on a preventive medicine used CGRP inhibitors, over 10 years there would be national indirect cost savings of $396 billion, as well as 374 million fewer migraine days.

Currently, 27 medicines are in development for headache, including migraine.

Learn more at PhRMA.org